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Abstract
Background: Several studies investigated the association of anemia with health related quality of
life (HRQL) in patients with chronic disease. However, there is little evidence regarding the
association of anemia with HRQL in patients with chronic obstructive pulmonary disease (COPD).
Methods: This is a post-hoc analysis of a study which enrolled a population of adults aged 35–79
randomly selected from residents of Erie and Niagara Counties, NY, between 1996 and 2000. In
addition to demographic information and physical measurements, we obtained spirometry data and
hemoglobin levels. We used modified Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria to define COPD, and World Health Organization (WHO) criteria to define
anemia. To assess HRQL we used the Short Form-36 (SF-36) to assess physical functioning (PF),
physical component summary (PCS) measures and mental component summary (MCS) measures.
Results: In the entire study population (n = 2704), respondents with anemia had lower scores on
the physical functioning domain [45.4 (SD10.9) vs. 49.2 (SD 9.1); p < 0.0001]. Among patients with
COPD (n = 495) the PF scores (39.9 vs. 45.4) and the PCS (41.9 vs. 45.9) were significantly lower
in individuals with anemia compared to those without. In multiple regression analysis, the
association between hemoglobin and PCS was positive (regression coefficient 0.02, p = 0.003).
There was no significant association of hemoglobin with PF scores or the mental component
summary measure after adjusting for covariates in patients with COPD.
Conclusion: In patients with moderate to very severe COPD anemia may be associated with
worse HRQL. However, co-morbidities may explain part or all of this association in these patients.
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Background
Health related quality of life (HRQL) is an important clin-
ical outcome for patients with advanced lung disease and
their health care providers [1]. This outcome measure
helps differentiate between individuals with varying
severity of lung disease and allows to evaluate how much
impact a specific intervention has on patients' lives.
Fatigue is a frequent symptom in patients with chronic
obstructive pulmonary disease (COPD). Nearly half of the
patients with COPD report fatigue every day with negative
impact on cognitive, physical, and psychosocial function-
ing [2]. Thus, fatigue adversely affects HRQL. Fatigue is
the primary symptom of anemia [3]. Dyspnea is another
manifestation of anemia because of reduced oxygen carry-
ing capacity of the blood. Thus, if patients with COPD suf-
fer from anemia, then fatigue and dyspnea may be worse.
Treatment of anemia, therefore, could have favorable
effects on fatigue and dyspnea, and, in turn, improve
HRQL. In fact, anemia is one of the most treatable cause
of fatigue in general [4].
HRQL and anemia have been extensively studied in
patients with other morbidities including renal failure
and cancer. For example, in patients with end-stage renal
diseases investigators showed a strong association
between HRQL, hospitalizations, and survival in those
with higher hemoglobin levels [5]. Some, but not all stud-
ies suggest that HRQL may improve in cancer patients
treated with erythropoietin [6-9].
There is limited published evidence about the association
of anemia with HRQL in individuals with COPD. We
identified three studies that evaluated the prevalence of
anemia in patients with COPD. In one study the preva-
lence of anemia was 36% in COPD patients randomly
selected from an outpatient clinic [10]. In another study
enrolling 58 patients the prevalence was 48% [11]. The
latter study also found a significant correlation between
severity of anemia and severity of COPD [11]. A recent
study evaluating anemia and inflammation in COPD
patients found a 13% prevalence of anemia in patients
with COPD [12].
Anemia may be under-diagnosed and it may have adverse
effects on fatigue and, thus, HRQL in patients with COPD.
If this were the case, treatment of anemia may improve
both symptoms and HRQL in this patient population.
Therefore, we evaluated whether anemia or hemoglobin
levels are associated with HRQL in individuals with
COPD randomly selected from the general population.
Methods
Study population
This is a post-hoc analysis of a study which enrolled par-
ticipants from a general population sample from Erie and
Niagara Counties, New York, as previously described [13].
In brief, we randomly selected residents of Eric and Nia-
gara counties age 35 to 64 yr from the New York State
Department of Motor Vehicles records. For participants
aged 65 to 79 yr we used the rolls of the Health Care
Finance Association. We assigned a computer-generated
random number to each person on the complete lists of
all potential participants supplied by the New York State
Department of Motor Vehicles and the Health Care
Finance Association. We then sorted potential partici-
pants with ascending numbers according to their ran-
domly assigned number and they were then contacted in
sequential fashion. We mailed introductory letters to
potential interviewees before the interviewers' telephone
calls. Participants receive up to 12 callbacks. We recruited
a total of 4065 subjects from 1996 to 2001. The study was
reviewed by the Institutional Review Board of SUNY at
Buffalo. All participants signed an informed consent at the
time of enrollment.
From the present analysis we excluded participants for the
following reasons: missing pulmonary function tests (n =
771); missing blood determination of hemoglobin (n =
100); missing scores on the HRQL measures (n = 143);
pulmonary function tests were unacceptable or not repro-
ducible (n = 207); race other than Caucasian or African-
American (n = 35); missing information on height, smok-
ing status, pack-years of smoking cigarettes, and education
(n = 41); and missing information on co-morbidity data
(liver cirrhosis, myocardial infarction, renal diseases or
diabetes) (n = 64). Complete data were available for 2704
participants, of whom 495 were classified as having mod-
erate to very severe COPD as described below.
Interview
The examination included both an in-person interview
that addressed a number of life-style habits, including
questions on the duration and intensity of lifetime ciga-
rette smoking, and a self administered questionnaire. The
questionnaire included questions on education, medical
history, and vitamin supplement use. For this study we
used the Short Form-36 (SF-36) which SF-36 is the most
widely used generic instrument for measuring HRQL [14].
We used co-morbidity data from the questionnaire for
multivariate and multivariable analyses. We asked partic-
ipants whether they were told by a physician or other
medical personnel that they have or have had a particular
condition. For these analyses, we considered liver cirrho-
sis, diabetes, myocardial infarction, and renal diseases as
covariates. We did not include patients with cancer in ourBMC Pulmonary Medicine 2006, 6:23 http://www.biomedcentral.com/1471-2466/6/23
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analysis. Before the end of the interview, trained person-
nel reviewed all answers in the questionnaire and partici-
pants clarified any uncertain aspects.
Pulmonary function tests
Trained personnel performed spirometry between 6:30
and 9:30AM following the American Thoracic Society
(ATS) guidelines on the Standardization of Spirometry,
1994 update [13,15]. We calculated forced Expiratory Vol-
ume in one second (FEV1) and Forced Vital Capacity
(FVC) prediction equations for men and women sepa-
rately with values obtained from the included participants
who were lifelong nonsmokers. We used a dummy varia-
ble for race (Caucasian = 0, African-American = 1) and
included 388 men and 538 women who never smoked
and did not report a history of chronic lung disease.
We obtained the following equations for men:
Predicted FEV1= -1.38165 - 0.02993 × age (years) +
3.82787 × height (m) - 0.42160 × race
Predicted FVC = -3.23510 - 0.03333 × age (years) +
5.56883 × height (m) - 0.51062 × race
For women we obtained the following equations:
Predicted FEV1= -0.00438 - 0.02673 × age (years) +
2.57782 × height (m) - 0.33534 × race
Predicted FVC = -0.94723 - 0.02813 × age (years) +
3.64983 × height (m) - 0.52404 × race
We then used the predicted FEV1 and FVC to calculate per-
cent-predicted for each of these parameters. We catego-
rized the participants into stages according to the Global
Initiative for Chronic Obstructive Lung Disease (GOLD)
criteria [16]. The stages of COPD in our study are based on
pre-bronchodilator spirometry parameters including
FEV1/FVC and FEV1. We did not use symptoms to define
stages because we did not assess symptoms according to
GOLD criteria and, hence categorized patients into stages
2 – 4. Of the 2704 participants, 2206 were in Stage 0, 3 in
Stage 1, 434 in Stage 2, 55 in Stage 3 and 6 in Stage 4. So
by combining Stages 2–4 we had 495 participants with
moderate to very-severe COPD.
Blood determinations
We determined anemia based on measurement of hemo-
globin from a fasting blood sample drawn between 7:30
and 9:30 AM. Trained personnel processed the samples
within 30 min, frozen at -80°C, and analyzed samples in
batches. An automated differential cell blood count was
completed using a Coulter Counter (Beckman Coulter,
Inc., Fullerton, CA).
Anthropometry
The personnel followed a detailed protocol to measure
body weight using a balance beam scale (Detecto, Inc.,
Webb City, MO) and height using a standardized scales
(Perspective Enterprises, Kalamazoo, MI).
Health related quality of life (HRQL) indicators
The SF-36 contains 36 items contributing to eight
domains measuring physical function (10 items), role
limitations-physical (4 items), bodily pain (2 items),
vitality (4 items), general health perceptions (5 items),
role limitations-emotional (3 items), social function (2
items), and mental health (5 items). These eight domains
are used to calculate the two component summary meas-
ures: Physical and Mental. Higher scores on any of the
domains or summary scores indicate that the participant
has better HRQL. The validity of the 8 domains and the 2
summary measures of the SF-36 has been widely investi-
gated for the general population and for a wide variety of
patient groups [14,17].
A priori, we determined that we would use three SF-36
measures as the main outcomes for our analysis: physical
functioning (PF), physical component summary (PCS)
measures and mental component summary (MCS) meas-
ures.
Statistical analysis
We used SAS® statistical software V9 (Copyright (c) 2002
by SAS Institute Inc., Cary, NC, USA) for the analyses and
calculated individual scale scores of the SF-36 using pub-
lished algorithms [18]. We computed raw SF-36 scores
and then transformed these scores to the commonly used
0 – 100 normed metric [18]. We determined a priori to
focus our analysis on the physical functioning domain
and the two SF-36 summary scores.
Definitions
We defined anemia using hemoglobin levels of less than
12 g/dl of hemoglobin in women and less than 13 mg/dl
in men using the WHO criteria [19]. Never-smokers were
defined as those who had smoked less than 100 cigarettes
during their entire lifetime and we derived pack-years of
smoking exposure from total years of smoking multiplied
by the number of cigarettes per day divided by 20.
Covariates
We considered the following covariates in the analyses:
education (years of education used as a continuous varia-
ble), gender, race, age, cumulative tobacco smoke expo-
sure (pack-years of smoking) and the co-morbidities liver
cirrhosis, diabetes, myocardial infarction, and renal dis-
eases as described earlier. We used education as an indica-
tor of socioeconomic status. We compared theBMC Pulmonary Medicine 2006, 6:23 http://www.biomedcentral.com/1471-2466/6/23
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demographic data for participants with anemia and those
without anemia using the unpaired t-test and chi-square.
To exclude outliers in the data we examined studentized
residuals in the regression procedure, and we excluded
observations from our analysis if the residual was 2.5 or
higher. For physical functioning there were 11 outliers, for
PCS there were 6 outliers and for MCS there were 14 out-
liers. Unadjusted mean scores of the outcome variables
were then generated for the two groups among partici-
pants with COPD using a General Linear Model (GLM).
Applying Analysis of Covariance (ANACOVA) we calcu-
lated mean scores after adjusting for the aforementioned
covariates.
Main analysis
Based on quartile analysis by gender we generated scores
for each of the three outcome variables (physical func-
tioning and the two SF-36 summary scores) across four
levels of anemia to investigate trends. We then performed
bivariate analyses of the HRQL measures and the inde-
pendent variables as well as the covariates. To account for
lack of linearity in our outcome variables based on trend
analysis we used log transformation of each of the out-
come variables in our regression analysis. For physical
functioning total pack years of smoking, history of myo-
cardial infarction and renal diseases were not included
because they were not statistically significant in the bivar-
iate analyses. For PCS we did not include the following
variables in our final model because they were not statis-
tically significant: pack years of smoking, gender, history
of myocardial infarction and renal diseases. We used back-
ward elimination multiple linear regression analysis to ana-
lyze the relationship between anemia and the three
outcome variables in participants with COPD after adjust-
ment for other covariates in the model. In all analyses, we
defined significance as p < 0.05.
Results
We analyzed the demographic characteristics and the
mean scores for all eligible participants by anemia status
and in the entire study group (N = 2704) (Data not
shown). The prevalence of anemia in the included popu-
lation was 5.3%. There was no significant difference in
mean age, gender distribution, and history of myocardial
infarction between the two groups (anemia vs. no ane-
mia). The mean physical functioning score and the PCS
were significantly lower in participants with anemia.
There was no significant difference between the two
groups in MCS score, total pack years of smoking, and
FEV1. The number of African-American participants was
significantly higher in the group with anemia. In regards
to other co-morbidities the group with anemia appeared
to have significantly higher prevalence of diabetes, renal
diseases, and liver cirrhosis. Of all participants, 495 were
classified as moderate to severe COPD. Characteristics of
excluded participants were similar to those mentioned
above (mean age 59.4 years (SD 12.4), 46.7% male and
88.6% Caucasian). Figure 1 shows the distribution of par-
ticipants by GOLD stages in a pie-chart (note that we did
not specifically assess these stages because we completed
the evaluation before publication of the GOLD criteria).
Distribution of GOLD stages in the study population (pre-bronchodilator spirometry) Figure 1
Distribution of GOLD stages in the study population (pre-bronchodilator spirometry).BMC Pulmonary Medicine 2006, 6:23 http://www.biomedcentral.com/1471-2466/6/23
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Table 1 shows the demographic data for the group of par-
ticipants with COPD. The prevalence of anemia was 7.5%.
There was no difference between those with and without
anemia in their average age, gender distribution, history
of renal diseases, history of myocardial infarction, years of
education, and FEV1. In those with anemia there was a sig-
nificantly higher percentage of participants with diabetes.
Unadjusted analysis showed significantly lower physical
functioning (p = 0.002) and PCS (p = 0.02) scores but not
MCS scores in COPD patients with anemia (Table 2).
When we examined the data after stratifying by gender we
found that the PF and PCS scores are significantly differ-
ent between the two groups only for females (36.3 vs. 44.6
for PF and 39.2 vs. 45.5 for PCS). There is no significant
difference between the scores for males. However, after
adjusting for covariates, both the physical functioning
scores and the PCS were not statistically significantly
related to anemia (Table 3).
Table 4 shows results of multivariable regression analysis
for physical functioning. After adjusting for covariates
there was no significant association between hemoglobin
and the log-transformed physical functioning score (p
value: 0.35). For PCS we observed a significant association
between hemoglobin and log-transformed PCS (p =
0.003, Table 5). There was also no significant association
between MCS and hemoglobin after adjusting for covari-
ates.
Discussion
We analyzed the association between anemia and HRQL
in individuals with COPD in a population-based sample.
In these individuals, HRQL (PCS) assessed with the SF-36
was negatively and significantly associated with hemo-
globin levels even after adjustment for co-variates.
Although we found no statistically significant associations
with the MCS or the PF domain of the SF-36 after adjust-
ment for covariates, these results suggest that low hemo-
globin levels are associated with impaired HRQL in
individuals with moderate or severe COPD.
Our study has several strengths. To our knowledge there is
no information from population based studies on the
association between anemia and HRQL in individuals
with COPD and, thus, this study provides new informa-
Table 2: Summary of Unadjusted Hemoglobin Analysis in Subjects with COPD (Stage 2, 3, 4 of GOLD Criteria)
Outcome Variables Unadjusted Group Means (Std. Error) P-Value
Anemia No Anemia
Physical Functioning Scores (n = 37) 39.98 (1.68) (n = 447) 45.36 (0.48) 0.002
PCS (n = 37) 41.95 (1.54) (n = 452) 45.86 (0.44) 0.02
MCS (n = 37) 49.83 (1.06) (n = 444) 49.07 (0.30) 0.49
Table 1: Demographic Characteristics of Subjects with COPD by Anemia Status (n = 495)
Characteristic Anemia (n= 37) No Anemia (n= 458) Total (n= 495) P-Value for Difference
Age (Means, SD) 65.05 (10.45) 64.07 (9.94) 64.15 (9.97) 0.57
HGB (Means, SD) 11.51 (1.05) 14.63 (1.11) 14.40 (1.38) <0.0001
Men (n, %) 19 (51.35) 277 (60.48) 296 (54.80) 0.28
Years of Education (Mean, SD) 12.46 (2.59) 12.84 (2.43) 12.81 (2.44) 0.36
Race (n, %) <0.0001
Caucasian 25 (67.57) 426 (93.01) 451 (91.11)
African American 12 (32.43) 32 (6.99) 44 (8.89)
Myocardial Infarction (n, %) 3 (8.11) 53 (11.57) 56 (11.31) 0.52
Renal Disease (n, %) 2 (5.41) 8 (1.75) 10 (2.02) 0.13
Diabetes (n, %) 14 (37.84) 68 (14.85) 82 (16.57) 0.0003
Smoking Status (n, %) 0.09
Never Smoked 13 (35.14) 107 (23.36) 120 (24.24)
Current Smoker 5 (13.51) 129 (28.17) 134 (27.07)
Former Smoker 19 (51.35) 222 (48.47) 241 (48.69)
Total Pack Years Smoked 18.65 (22.67) 28.33 (26.71) 27.60 (26.53) 0.03
FEV1, % Predicted 68.43 (8.23) 66.04 (12.69) 66.22 (12.42) 0.26BMC Pulmonary Medicine 2006, 6:23 http://www.biomedcentral.com/1471-2466/6/23
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tion. In addition, we collected detailed information on
covariates and confounders that allowed for adjusted
analyses.
The study also has some limitations. First, we neither eval-
uated respiratory symptoms nor measured post-bron-
chodilator FEV1. Thus, we could not apply the original
GOLD criteria published after initiation of this study.
However, we used a transparent modified approach of the
GOLD criteria to define COPD that could improve com-
parison with future studies. Many epidemiological studies
will be limited in that they do not collect post-bronchodi-
lator spirometry. Second, readers should not infer causa-
tion from the cross-sectional association of HRQL
impairment and anemia in individuals with COPD,
because it is possible that residual confounding by comor-
bidities is responsible for the observed association.
Evidence for an association between HRQL and hemo-
globin levels is limited to two studies published in
abstract form [10,11]. The study by Stanbrook et al.
explored the prevalence of anemia in COPD patients [10].
The authors randomly selected patients from outpatients
of a pulmonary subspecialty clinic and from a pulmonary
rehabilitation program. Anemia was defined as <14 g/dl
for men and <12 g/dl for women. Prevalence of anemia
was 36%. Park et. al performed another retrospective
study to determine the prevalence of anemia in COPD
patients [11]. Data from 58 COPD patients recruited from
a pulmonary clinic showed anemia to be present in 48%.
The prevalence of anemia in our study was considerably
less than that observed in these clinic-based studies (7.5%
vs. 36% and 48%). A likely explanation for this difference
is that individuals from the general population partici-
pated in our study rather than patients in tertiary clinics
who may be sicker than participants in a general popula-
tion study. Hence it is possible that stronger associations
between anemia and HRQL might be observed among
patients with severe COPD drawn from a tertiary lung
clinic.
We did not specifically assess hemoglobinopathy in this
study despite of race being an important variable. To
inform this issue we evaluated the Mean Corpuscular Vol-
ume (MCV) which was available for all included subjects.
There was no statistical difference in mean MCV or mean
hemoglobin between African-Americans and Caucasians
in either the overall population or in those with moderate
to very severe COPD (Data not shown). Although this lat-
ter evaluation does not address the issue directly it lends
some support to the notion that hemoglobinopathies did
not play an important role or they were similarly distrib-
uted in these two races.
The difference between males and females deserve some
consideration. We are unable to explain why the differ-
ence in HRQL scores was greater in women compared to
men. One possible conclusion is that females with ane-
mia perceive greater impairment of their HRQL compared
to males as has been seen in various studies and reviews
Table 4: Multiple Linear Regression Analysis for Association Between Hemoglobin Level and Physical Functioning Scale (log 
transformed) after Adjusting for Baseline Characteristics (Following variables were removed because of lack of significant association in 
bivariate analysis: pack years of smoking, history of myocardial infarction and renal diseases)
Variable (n = 484) Regression Coefficient P Value R2
Beta Std Error
Hemoglobin 0.01 0.01 0.35 0.1214
Age -0.003 0.001 0.002
Gender (Female ref) 0.06 0.03 0.04
Race (Caucasian ref) -0.11 0.04 0.01
Education 0.02 0.005 0.002
Diabetes -0.13 0.03 <0.0001
Table 3: Summary of Adjusted Hemoglobin Analysis in Subjects with COPD (adjusted for age, gender, years of education, pack years 
of smoking, history of myocardial infarction, renal diseases or diabetes and race)
Outcome Variables Adjusted Group Means (Std Error) P-Value
Anemia No Anemia
Physical Functioning Scores (n = 37) 39.26 (2.27) (n = 447) 42.15 (1.90) 0.095
PCS (n = 37) 40.62 (2.08) (n = 452) 43.05 (1.70) 0.14
MCS (n = 37) 51.81 (1.48) (n = 444) 51.34 (1.23) 0.68BMC Pulmonary Medicine 2006, 6:23 http://www.biomedcentral.com/1471-2466/6/23
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[20-23]. There has been only one systematic review which
has addressed this issue specifically and it suggests that
women may report symptoms and worse HRQL com-
pared to men [24]. However, one should also note that
our results come from an explorative post-hoc analyses
and it is possible that they represent a false positive result.
Although we included and adjusted for some comorbidi-
ties, we did not account for some of the disease processes
which can influence HRQL such as congestive heart fail-
ure and neuromuscular disorders. Medications such as
Angiotensin Converting Enzyme inhibitors have been
associated with anemia [25], but we did not adjust for this
possible confounder in our analysis, because the evidence
is limited and the cause effect relation not established.
The association between HRQL and anemia as a dichoto-
mous variable was weaker (Table 2) than the association
between HRQL and hemoglobin levels (Table 4). The lat-
ter is a result of the increased power in the analysis using
the continuous variable compared to the binary variable
of presence of anemia. However, adjustment for comor-
bidities weakened the relation between hemoglobin levels
and HRQL suggesting that comorbidities play a role in the
association between anemia and HRQL impairment.
Using the PCS of the SF-36 reduces random error and
increases the importance attributed to impairment of
HRQL related to physical impairment. The latter is due to
the weighing of all 8 domain scores on the SF-36 that
make up the PCS. Although we speculated that low hemo-
globin levels may contribute to impairment of mental
function assessed with the MCS of the SF-36, we did not
observe an association between the two variables. Thus,
anemia may primarily affect physical functioning as a
whole and have less impact on any emotional conse-
quences of fatigue and dyspnea.
Although there are several disease specific HRQL ques-
tionnaires for individuals with COPD [26-28], our study
utilized a generic instrument, the SF-36. The SF-36 has
shown good discriminative properties; that is the ability
to differentiate between individuals with better or worse
HRQL cross-sectionally [17] Our study aimed at the gen-
eral population of which we did not – a priori – know
who had COPD. For our analysis, discriminative proper-
ties were of primary concern and therefore, the SF-36 rep-
resented an appropriate measurement tool [29].
What implications do our findings have for clinical prac-
tice? We have not established a causal relation between
lower hemoglobin levels and HRQL. Thus, no treatment
recommendations follow from our results. However, we
encourage practitioners to explore underlying etiologies
for anemia as this may have implications for HRQL in an
individual with COPD.
Conclusion
In conclusion, our analyses provide evidence for a nega-
tive association between HRQL and hemoglobin levels in
individuals with moderate -to-severe COPD. Co-morbidi-
ties appear to explain part of the observed association for
PF and MCS but not for PCS. If, in fact, there is a causal
relationship, there could be important implications for
treatment of anemia to improve HRQL in individuals
with COPD. However, additional observational studies
are required to confirm our findings before intervention
studies can be advocated in individuals with low hemo-
globin levels and COPD.
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